These findings demonstrate that ras mutations are a marker for aggressive cancer behavior and indicate a possible role of ras genotyping to identify thyroid carcinoma subsets associated with poor prognosis.
In a community setting, 57% of all patients with GBM and only 32% of older patients received RT with concomitant and adjuvant temozolomide. In patients with surgical resection who were eligible for chemoradiation, initiation of RT ≤42 days was associated with better progression-free survival.
proteinuria (27.3%), stomatitis (11.4%). Nine (20.5%) pts required treatment discontinuation and reasons were due to death, PD and AE in 5 (11.4%), 2 (4.5%) and 2 (4.5%) pts, respectively. Five deaths occurred. Dose reductions to 20, 18, 14 and 10 mg were in 10 (22.7%), 3 (6.7%), 7 (15.9%) and 7 (15.9%) pts, respectively; 16 (36.4%) pts did not require dose reduction.Conclusions: 61,4 % ORR shows good efficacy of lenvatinib in population of pts with poor performance status (ECOG 1-2).Legal entity responsible for the study: The authors.
Acromegaly is a rare, chronic endocrine disease, characterized by enhanced growth hormone (GH) secretion and elevated insulin-like growth factor-I (IGF-I) levels, the most frequent cause of which is a pituitary adenoma 1• Persistently elevated GH and IGF-I levels lead to substantial morbidity and mortality 2 • Control of GH and IGF-1 secretion is decisive in improving survival, 3 and optimum management of the disease requires a reduction in GH levels to <2.5 ng/mL and normalisation of IGF-1 levels 3• Somatostatin analogues (SSAs) have become the pillar of acromegaly medical therapy in patients unsuitable for, or refusing surgery, after failure of surgical treatment, or in selected cases as primary treatment 4• Initial recommended doses of the SSA Lanreotide Autogel are 60, 90 and 120 mg administered every 28 days.Experience in Spanish hospitals indicated that a longer dosage interval could be used in well controlled patients with similar efficacy. 5 Starting dose for Lanreotide Autogel prescribed in clinical practice may differ from prescribing recommendations
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.